OMONTYS PRESERVATIVE FREE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omontys Preservative Free, and when can generic versions of Omontys Preservative Free launch?
Omontys Preservative Free is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and fourteen patent family members in thirty-four countries.
The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Omontys Preservative Free
Omontys Preservative Free was eligible for patent challenges on March 27, 2016.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMONTYS PRESERVATIVE FREE?
- What are the global sales for OMONTYS PRESERVATIVE FREE?
- What is Average Wholesale Price for OMONTYS PRESERVATIVE FREE?
Summary for OMONTYS PRESERVATIVE FREE
| International Patents: | 114 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | OMONTYS PRESERVATIVE FREE at DailyMed |
US Patents and Regulatory Information for OMONTYS PRESERVATIVE FREE
OMONTYS PRESERVATIVE FREE is protected by six US patents.
Patents protecting OMONTYS PRESERVATIVE FREE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Peptides that bind to the erythropoietin receptor
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Spacer moiety for poly (ethylene glycol) modified peptide based compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Erythropoietin receptor peptide formulations and uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-006 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMONTYS PRESERVATIVE FREE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-002 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-004 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-002 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMONTYS PRESERVATIVE FREE
See the table below for patents covering OMONTYS PRESERVATIVE FREE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2010536857 | ⤷ Sign Up | |
| New Zealand | 563042 | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds | ⤷ Sign Up |
| China | 1823088 | Novel peptides that bind to the erythropoietin receptor | ⤷ Sign Up |
| Mexico | PA05012314 | RADICAL SEPARADOR PARA PEPTIDO MODIFICADO CON POLIETILENGLICOL. (SPACER MOIETY FOR POLY(ETHYLENE GLYCOL) -MODIFIED PEPTIDES.) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
